Display options
Cite
Dawes M, Aloise MN, Ang JS, et al. Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. CMAJ Open. 2016;4(3):E528-E534doi: 10.9778/cmajo.20150070.
Dawes, M., Aloise, M. N., Ang, J. S., Cullis, P., Dawes, D., Fraser, R., Liknaitzky, G., Paterson, A., Stanley, P., Suarez-Gonzalez, A., & Katzov-Eckert, H. (2016). Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. CMAJ open, 4(3), E528-E534. https://doi.org/10.9778/cmajo.20150070
Dawes, Martin, et al. "Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study." CMAJ open vol. 4,3 (2016): E528-E534. doi: https://doi.org/10.9778/cmajo.20150070
Dawes M, Aloise MN, Ang JS, Cullis P, Dawes D, Fraser R, Liknaitzky G, Paterson A, Stanley P, Suarez-Gonzalez A, Katzov-Eckert H. Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. CMAJ Open. 2016 Sep 21;4(3):E528-E534. doi: 10.9778/cmajo.20150070. eCollection 2016. PMID: 27730116; PMCID: PMC5047800.
Copy Download .nbib Format: NLM
Share it on

CMAJ Open. 2016 Sep 21;4(3):E528-E534. doi: 10.9778/cmajo.20150070. eCollection 2016.

Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study.

CMAJ open

Martin Dawes, Martin N Aloise, J Sidney Ang, Pieter Cullis, Diana Dawes, Robert Fraser, Gideon Liknaitzky, Andrea Paterson, Paul Stanley, Adriana Suarez-Gonzalez, Hagit Katzov-Eckert

Affiliations

  1. Department of Family Practice (M. Dawes); GenXys Health Care Systems (M. Dawes, Aloise, Ang, Cullis, D. Dawes, Fraser, Liknaitzky, Stanley, Suarez-Gonzalez, Katzov-Eckert); Personalized Medicine Initiative (Cullis, Fraser); Department of Physical Therapy (D. Dawes); Faculty of Pharmaceutical Sciences (Paterson); Clinicare Pharmacists Inc. (Paterson); Department of Botany (Suarez-Gonzalez); Department of Biochemistry and Molecular Biology (Cullis), University of British Columbia, Vancouver, BC.

PMID: 27730116 PMCID: PMC5047800 DOI: 10.9778/cmajo.20150070

Abstract

BACKGROUND: Inappropriate prescribing increases patient illness and death owing to adverse drug events. The inclusion of genetic information into primary care medication practices is one solution. Our aim was to assess the ability to obtain and genotype saliva samples and to determine the levels of use of a decision support tool that creates medication options adjusted for patient characteristics, drug-drug interactions and pharmacogenetics.

METHODS: We conducted a cohort study in 6 primary care settings (5 family practices and 1 pharmacy), enrolling 191 adults with at least 1 of 10 common diseases. Saliva samples were obtained in the physician's office or pharmacy and sent to our laboratory, where DNA was extracted and genotyped and reports were generated. The reports were sent directly to the family physician/pharmacist and linked to an evidence-based prescribing decision support system. The primary outcome was ability to obtain and genotype samples. The secondary outcomes were yield and purity of DNA samples, ability to link results to decision support software and use of the decision support software.

RESULTS: Genotyping resulted in linking of 189 patients (99%) with pharmacogenetic reports to the decision support program. A total of 96.8% of samples had at least 1 actionable genotype for medications included in the decision support system. The medication support system was used by the physicians and pharmacists 236 times over 3 months.

INTERPRETATION: Physicians and pharmacists can collect saliva samples of sufficient quantity and quality for DNA extraction, purification and genotyping. A clinical decision support system with integrated data from pharmacogenetic tests may enable personalized prescribing within primary care.

Conflict of interest statement

See the end of the article.

References

  1. Mayo Clin Proc. 2015 Jun;90(6):716-29 - PubMed
  2. Clin Pharmacol Ther. 2016 Jul;100(1):63-6 - PubMed
  3. BMC Bioinformatics. 2010 Oct 28;11 Suppl 9:S10 - PubMed
  4. Nature. 2015 Oct 15;526(7573):343-50 - PubMed
  5. Pharmacogenomics. 2010 Apr;11(4):501-5 - PubMed
  6. Clin Pharmacol Ther. 2011 Mar;89(3):464-7 - PubMed
  7. Pharmacogenomics. 2014 Apr;15(5):655-65 - PubMed
  8. BMJ. 2015 Mar 11;350:h1059 - PubMed
  9. Pharmacogenet Genomics. 2014 Mar;24(3):139-45 - PubMed
  10. Aust Fam Physician. 2015 Jun;44(6):411-4 - PubMed
  11. Clin Pharmacol Ther. 2016 Aug;100(2):160-9 - PubMed
  12. BMJ. 2015 Nov 03;351:h5501 - PubMed
  13. Ann Pharmacother. 2007 Sep;41(9):1411-26 - PubMed
  14. Genome. 2015 Dec;58(12):527-40 - PubMed
  15. BMC Fam Pract. 2014 Apr 02;15:59 - PubMed
  16. Pharmgenomics Pers Med. 2016 Jan 19;9:1-6 - PubMed
  17. Pharmacogenomics. 2014 Sep;15(13):1677-86 - PubMed
  18. Hum Factors. 2015 Sep;57(6):1002-14 - PubMed
  19. J Am Med Inform Assoc. 2006 Mar-Apr;13(2):138-47 - PubMed
  20. Br J Gen Pract. 2013 Oct;63(615):e713-20 - PubMed
  21. BMJ. 2015 Sep 23;351:h4848 - PubMed
  22. J Am Med Inform Assoc. 2007 Jan-Feb;14(1):29-40 - PubMed
  23. Clin Pharmacol Ther. 2011 May;89(5):662-73 - PubMed
  24. J Am Med Inform Assoc. 2014 Feb;21(e1):e93-9 - PubMed
  25. JAMA. 2001 Nov 14;286(18):2270-9 - PubMed
  26. Eur J Clin Pharmacol. 2012 Apr;68(4):363-70 - PubMed
  27. J Med Econ. 2016;19(3):213-28 - PubMed
  28. Arch Intern Med. 2003 Nov 24;163(21):2625-31 - PubMed
  29. Health Rep. 2014 Jun;25(6):3-9 - PubMed
  30. N Engl J Med. 2003 Apr 17;348(16):1556-64 - PubMed
  31. Pharmacogenomics. 2014 May;15(7):963-76 - PubMed
  32. Ann Pharmacother. 2011 Jul;45(7-8):977-89 - PubMed
  33. J Patient Saf. 2016 Jun;12(2):69-74 - PubMed

Publication Types